Evidence map›Paper›PMID 32315273›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.

Elizabeth Sokol, Ami V Desai, Mark A Applebaum, Dominique Valteau-Couanet, Julie R Park, Andrew D J Pearson, Gudrun Schleiermacher, Meredith S Irwin, Michael Hogarty, Arlene Naranjo and 3 more

Abstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. [Clinical analysis of primary cervical neuroblastoma in children].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The prognostic role ofEuropean radiology · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Elizabeth SokolDepartment of Pediatrics and Lurie Children's Hospital, Northwestern University, Chicago, IL.
Ami V DesaiDepartment of Pediatrics and Comer Children's Hospital, University of Chicago, Chicago, IL.
Mark A ApplebaumDepartment of Pediatrics and Comer Children's Hospital, University of Chicago, Chicago, IL.
Dominique Valteau-CouanetInstitute Gustave Roussy, Villejuif, France.
Julie R ParkDepartment of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington.
Andrew D J PearsonPaediatric Drug Development, Children and Young People's Unit, Royal Marsden Hospital, London, United Kingdom.
Gudrun SchleiermacherDepartment of Pediatric, Adolescents and Young Adults Oncology and INSERM U830, Institut Curie, Paris, France.
Meredith S IrwinDepartment of Pediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada.
Michael HogartyDepartment of Pediatrics, University of Pennsylvania, Philadelphia, PA.
Arlene NaranjoDepartment of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL.
Samuel VolchenboumDepartment of Pediatrics and Comer Children's Hospital, University of Chicago, Chicago, IL.
Susan L CohnDepartment of Pediatrics and Comer Children's Hospital, University of Chicago, Chicago, IL.
Wendy B LondonDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

purposeThe Children's Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked International Neuroblastoma Pathology Classification (INPC) criteria. By definition, this leads to a duplication of the prognostic contribution of age. The individual histologic features underlying the INPC have prognostic strength and are incorporated in the International Neuroblastoma Risk Group classification schema. Here, we analyzed data in the International Neuroblastoma Risk Group Data Commons to validate the prognostic strength of the underlying INPC criteria and to determine whether a risk classification devoid of the confounding of age and INPC criteria will identify new prognostic subgroups. PATIENTS AND

methodsEvent-free survival of patients diagnosed between 1990 and 2002 (cohort 1; n = 10,104) and between 2003 and 2016 (cohort 2; n = 8,761) was analyzed. Recursive partitioning with univariate Cox models of event-free survival ("survival tree regression") was performed using (1) individual INPC criteria (age at diagnosis, histologic category, mitosis-karyorrhexis index (MKI), grade of differentiation) and (2) factors in (1) plus other COG-risk biomarkers (International Neuroblastoma Staging System [INSS] stage,

resultsThe independent prognostic ability of age, histologic category, MKI, and grade were validated. Four histologic prognostic groups were identified (< 18 months with low

conclusionReplacing INPC with individual histologic features in the COG risk classification will eliminate confounding, facilitate international harmonization of risk classification, and provide a schema for more precise prognostication and refined therapeutic approaches.

Indexed as

AdolescentAge FactorsBiomarkers, TumorChildChild, PreschoolCohort StudiesHumansInfantMitotic IndexNeoplasm GradingNeuroblastomaPrognosisYoung AdultBiomarkers, Tumor

Identifiers

PMID32315273
PMCPMC7280049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.